Figure 1.
Neurotensin expression in normal breast tissue.
a) Left, one µg of total RNA from HBEC or whole gland were reverse-transcribed and a PCR experiment specific for NTS was performed. Right, one µg of total RNA from HBEC cells (control, treated with 10 nM estradiol (E2) with or without 1 µM ICI 182780) was reverse-transcribed. A PCR experiment was performed using specific primers for NTS and GAPDH. b) Normal duct exposed to NTS antibody at 1/500 dilution (1), after pre-incubation with the antigen peptide for 2 h at 10 nM (2), or without primary antibody (3), and lobule exposed to NTS antibody (4). Normal tissue exposed to NTS antibody at 1/500 dilution adjacent to tumor duct (5), lobule (6). The original magnification was 200×.
Figure 2.
Neurotensin expression in IDCs.
a) NTS immunohistochemistry was performed on IDCs, ductal (1) and invasive (2) components, magnification 200× for (1) and 400× for (2). b) NTS and NTSR1 transcripts in IDCs. One µg of total RNA from 11 patients with IDCs were reverse-transcribed, and specific PCR was performed for NTS, NT-1 receptor, or GAPDH (control). The SBR grade is indicated below each line. c) Example of NTS and NTSR1 regional co-localization by immunohistochemistry for NTS (right) and NTSR1 (left) at the original magnification 400×.
Table 1.
Patients clinical characteristics.
Table 2.
Prognosis factors and deaths stratified by NT expression in the ductal and invasive components of IDCs.
Figure 3.
NTSR1 expression in IDCs and global survival duration.
Kaplan-Maier analysis for global survival duration in both groups with low (<80%) and high (≥80%) NTSR1 expression. Probability of overall death for patients with high NTSR1 expression (n = 38) versus patients with low NTSR1 expression (n = 68).
Table 3.
Prognosis factors and deaths stratified by NT-1 receptor expression in the invasive component of IDCs.
Table 4.
Correlation of the subpopulation co-expressing NT and NT1 receptor with the major prognosis factors.